Clinical trial NCT02571192: A Study to Investigate How the Study Drug SHP626 is Eliminated From the Body After One Dose
Official title: A Phase 1, Open-label Study to Investigate the Absorption, Distribution, Metabolism, and Excretion of [14C]-SHP626 Following a Single Oral Dose in Healthy Male Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Non-Alcoholic Steatohepatitis
Keywords: ADME
Lead sponsor: Mirum Pharmaceuticals, Inc.
Sponsor class: INDUSTRY
First posted: 2015-10-08
Enrollment: 8
Sex: MALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to determine how SHP626 is absorbed and excreted from the body in healthy males.


Eligibility criteria: Inclusion Criteria:

1. Age between 18 and 50 years, inclusive, at the time of consent.
2. Must be considered healthy. Healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead ECG, hematology, thyroid panel (includes T3, T4 and TSH at Screening only), blood chemistry, coagulation and urinalysis
3. Must have a body mass index between 18.0-30.0kg/m² inclusive with a body weight \>50 kg (110 lbs).
4. Ability to swallow all investigational product.
5. A minimum of 1 bowel movement per day.

Exclusion Criteria:

1. History of any hematological, hepatic, respiratory, cardiovascular, renal, neurological or psychiatric disease, gallbladder removal, gastric bypass surgery, ileal resection, any small intestinal resection,or current or recurrent disease that could affect the action, absorption, or disposition of the investigational product, or clinical or laboratory assessments.
2. Current or relevant history of physical or psychiatric illness.
3. Known or suspected intolerance or hypersensitivity to the investigational product, or closely-related compounds, or any of the stated ingredients.
4. Significant illness, as judged by the investigator, within 2 weeks of the dose of investigational product.
5. Known history of alcohol or other substance abuse within the last year.
6. Donation of blood or blood products (eg, plasma or platelets) within 60 days prior to the dose of investigational product.
7. Within 30 days prior to the dose of investigational product:

   * Have used an investigational product (if elimination half-life is \<6 days, otherwise 5 half-lives).
   * Have been enrolled in a clinical study (including vaccine studies) that, in the investigator's opinion, may impact this Shire-sponsored study.
   * Have had any substantial changes in eating habits, as assessed by the investigator.
8. Confirmed systolic blood pressure \>139mmHg or \<89mmHg, and diastolic blood pressure \>89mmHg or \<49mmHg.
9. Twelve-lead ECG demonstrating QTc \>450 msec at screening. If QTc exceeds 450msec, the ECG should be repeated 2 more times and the average of the 3 QTc values should be used to determine the subject's eligibility.
10. A positive screen for drugs of abuse at Screening or a positive screen for alcohol or drugs of abuse at Check-in (Day -1).
11. Male subjects who consume more than 21 units of alcohol per week or 3 units of alcohol per day.
12. A positive human immunodeficiency virus antibody screen, hepatitis B surface antigen, or hepatitis C virus antibody screen.
13. Use of tobacco in any form
14. Routine consumption of more than 2 units of caffeine per day
15. Current use of any medication including over-the-counter, herbal, or homeopathic preparations
16. An inability to follow a standardized diet and meal schedule or inability to fast
17. Have participated in a \[14C\]-study within the last 6 months prior to the dose of investigational product.
18. Exposure to clinically significant radiation within 12 months prior to the dose of investigational product

Primary outcomes:
measure: Pharmacokinetic parameters will be determined from the plasma and blood concentration time data of total radioactivity and from the plasma concentration-time data for SHP626 by non-compartmental analysis.
timeFrame: Day 1 to day 10
measure: Total radioactivity (RAD) in whole blood and plasma
timeFrame: Day 1 to day 10
measure: To determine the total RAD in urine and feces.
timeFrame: Day 1 to day 10
measure: Maximum plasma concentration (Cmax) of 50mg [14C]-SHP626 and RAD occurring at time of maximum observed concentration (tmax)
timeFrame: Day 1 to day 10
measure: Area under the plasma concentration curve (AUC0-t) of 50mg [14C]-SHP626 and RAD from the time of dosing to the last measurable concentration
timeFrame: Day 1 to Day 10
measure: Area under the plasma concentration curve (AUC0-∞ ) of 50mg [14C]-SHP626 and RAD extrapolated to infinity, calculated using the observed value of the last non-zero plasma concentration
timeFrame: Day 1 to Day 10
measure: First order rate constant associated with the terminal portion of the plasma curve terminal half-life (t½) for 50mg [14C]-SHP626 and RAD
timeFrame: Day 1 to Day 10
measure: Total body clearance (CL/F ) of 50mg [14C]-SHP626 and RAD for extravascular administration divided by the fraction of dose absorbed
timeFrame: Day 1-10
measure: Volume of distribution (Vz/F ) of 50mg [14C]-SHP626 and RAD associated with the terminal slope following extra-vascular administration divided by the fraction of dose absorbed
timeFrame: Day 1-10
measure: Cumulative amount (Aef )of RAD recovered in stool over the dosing interval
timeFrame: Day 1-10
measure: Excreted Percent of RAD recovered in stool over the dosing interval
timeFrame: Day 1-10
measure: Cumulative amount (Aeu ) of RAD recovered in urine over the dosing interval
timeFrame: Day 1-10
measure: Excreted Percent of RAD recovered in urine over the dosing interval
timeFrame: Day 1-10
measure: Renal Clearance (CLR ) of 50mg [14C]-SHP626
timeFrame: Day 1 -10
Secondary outcomes:
measure: Characterize and identify metabolites of [14C]-SHP626 in plasma by accelerator mass spectrometry for radioactivity quantification
timeFrame: Day 1 to day 10
measure: Characterize and identify metabolites of [14C]-SHP626 in urine by accelerator mass spectrometry for radioactivity quantification
timeFrame: Day 1 to day 10
measure: Characterize and identify metabolites of [14C]-SHP626 in feces by liquid scintillation counting
timeFrame: Day 1 to day 10
measure: Assess the safety and tolerability of [14C]-SHP626 by adverse events (AEs) defined as changes, including changes from baseline in physical examination findings
timeFrame: Screening to day 7
measure: Changes from baseline in vital signs
timeFrame: Screening to day 7
measure: Changes from baseline in ECGs
timeFrame: Screening to day 7
measure: Changes from baseline in hematology
timeFrame: Screening to day 7
measure: Changes from baseline in coagulation
timeFrame: Screening to day 7
measure: Changes in baseline in urinalysis
timeFrame: Screening to day 7
measure: Changes in baseline in chemistry
timeFrame: Screening to day 7
Other outcomes:
Locations:
city: Madison
country: United States
facility: Covance Madison Clinical Research Unit
state: Wisconsin
Study officials:
affiliation: Covance Clinical Pharmacology
name: Nicholas Siebers, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Siebers N, Palmer M, Silberg DG, Jennings L, Bliss C, Martin PT. Absorption, Distribution, Metabolism, and Excretion of [14C]-Volixibat in Healthy Men: Phase 1 Open-Label Study. Eur J Drug Metab Pharmacokinet. 2018 Feb;43(1):91-101. doi: 10.1007/s13318-017-0429-7.